HLA class II haplotype associations with inflammatory bowel disease in Jewish (Ashkenazi) and non-Jewish caucasian populations

Human Immunology

Volumn 61, Issue 3, 2000, Pages 326-333

  Trachtenberg, E A ^a   Yang, H ^b   Hayes, E ^a   Vinson, M ^a   Lin, C ^b   Targan, S R ^b   Tyan, D ^c   Erlich, H ^a,d   Rotter, J I ^b  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b Inflammatory Bowel Disease Center   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

Crohn's disease; HLA class II association; IBD; Ulcerative colitis

Indexed keywords

HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; HLA DR ANTIGEN;

ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; CROHN DISEASE; DISEASE PREDISPOSITION; ENTERITIS; FEMALE; HAPLOTYPE; HUMAN; IMMUNOGENETICS; JEW; MAJOR CLINICAL STUDY; MALE; OLIGONUCLEOTIDE PROBE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ULCERATIVE COLITIS;

CALIFORNIA; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HLA-D ANTIGENS; HLA-DP ANTIGENS; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; INFLAMMATORY BOWEL DISEASES; JEWS; MALE;

EID: 0033993733     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(99)00134-2     Document Type: Article

References (42)

1. Yang H., McElree C., Roth M.-P., Shanahan F., Targan S.R., Rotter J.I. Familial empirical risks for inflammatory bowel disease differences between Jews and non-Jews . Gut. 34:1993;517.
2. Roth M., Peterson G.M., McElree C., Vadheim C.M., Panish J.F., Rotter J.I. Familial empiric risk estimates of inflammatory bowel disease in Ashkenazi Jews. Gastroenterology. 96:1989;1016.
3. Satsangi J., Parkes M., Louis E., Hashimoto L., Kato N., Welsh K., Terwilliger J.D., Lathrop G.M., Bell J.I., Jewell D.P. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet. 14:1996;199.
4. Hugot J.P., Laurent-Puig P., Gower-Rousseau C., Olson J.M., Lee J.C., Beaugerie L., Naom I., Dupas J.L., Van Gossum A., Orholm M., Bonaiti-Pellie C., Weissenbach J., Mathew C.G., Lennard-Jones J.E., Cortot A., Colombel J.F., Thomas G. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature. 379:1996;821.
5. Parkes M., Satsangi J., Lathrop G.M., Bell J.I., Jewell D.P. Susceptibility loci in inflammatory bowel disease. Lancet. 348:1996;1588.
6. Yang H., Plevy S.E., Taylor K., Tyan D., Fischel-Ghodsian N., McElree C., Targan S.R., Rotter J.I. Linkage of Crohn's disease to the major histocompatibility complex region is detected by multiple non-parametric analyses. Gut. 44:1999;519.
7. Yang H, Rotter JI: Inflammatory Bowel Disease: Principles and Practice of Medical Genetics, 3rd edn. In Rimon DL, Connor JM, Pyritz RE (eds): New York: Churchill Livingstone, 1997:1533.
8. Bouma G., Xia B., Crusius J., Bioque G., Koutroubakis I., Von Blomberg B., Meuwissen S., Pena A. Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin Exp Immunol. 103:1996;391.
9. Bouma G., Crusius J., Oudkerk Pool M., Kolkman J., VonBlomberg B., Kostense P., Giphart M., Schreuder G., Meuwissen S., Pena A. Secretion of tumor necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol. 43:1996;456.
10. Louis E., Satsangi J., Roussomoustakaki M., Parkes M., Fanning G., Welsh K., Jewell D. Cytokine gene polymorphisms in inflammatory bowel disease. Gut. 39:1996;705.
11. Bouma G., Poen A.C., Garcia-Gonzalez M.A., Th Schreuder G.M., Felt-Bersma R.J.F., Meuwissen S.G.M., Pena A.S. HLA-DRB1*03, but not the TNFA-308 promoter gene polymorphism confers protection against fistulizing Crohn's disease. Immunogenetics. 47:1998;451.
12. Plevy S.E., Targan S.R., Yang H., Fernandez D., Rotter J.I., Toyoda H. Tumor necrosis factor microsatellites define a Crohn's disease-associated haplotype on chromosome 6. Gastroenterology. 110:1996;1053.
13. Bouma G., Oudkerk P.M., Crusius J.B., Schreuder G.M., Hellemans H.P., Meijer B.U., Kostense P.J., Giphart M.J., Meuwissen S.G., Pena A.S. Evidence for genetic heterogeneity in inflammatory bowel disease (IBD); HLA genes in the predisposition to suffer from ulcerative colitis (UC) and Crohn's disease (CD). Clin Exp Immunol. 109:1997;175.
14. Satsangi J., Welsh K.I., Bunce M., Julier C., Farrant J.M., Bell J.I., Jewell D.P. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet. 347:1996;1212.
15. Toyoda H., Wang S., Yang H., Redford A., Magalong D., Tyan D., McElree C.K., Pressman S.R., Shanahan F., Targan S.R., Rotter J.I. Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology. 104:1993;741.
16. Yoshitake S., Kimura A., Okada M., Yao T., Sasazuki T. HLA class II alleles in Japanese patients with inflammatory bowel disease. Tiss Antigens. 53:1999;350.
17. Thorsby E. HLA associated diseases. Hum Immunol. 53:1997;1.
18. Powrie F. T cells in inflammatory bowel disease protective and pathogenic roles . Immunity. 3:1995;171.
19. Yang H., Rotter J.I., Toyoda H., Tyan D., McElree C.K., Lorder C., Targan S.R. Ulcerative colitis a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (anti-neutrophil cytoplasmic antibodies) markers . J Clin Invest. 92:1993;1080.
20. Annese V., Piepoli A., Napolitano G., et al. Are HLA and pANKA markers of genetic heterogeneity in ulcerative colitis? Gastroenterology. 108:1995;A771.
21. Andus T., Caesar D., Vogl J., et al. Association of HLA-DR15, p-ANCA and IL-1 receptor antagonist allele 2 with ulcerative colitis. Gastroenterology. 108:1995;A770.
22. Farrant J., Bunce M., Artlett C., et al. HLADR2 is a susceptibility marker for UC in British patients irrespective of ANCA positivity. Gastroenterology. 106:1994;A679.
23. Nakjima A., Matsuhashi N., Kodama T., Yazaki Y., Takazoe M., Kimura A. HLA-linked susceptibility and resistance genes in Crohn's disease. Gastroenterology. 109:1995;1462.
24. Futami S., Aoyama N., Hosaky Y., et al. DRB1*1502 allele, subtype of DR15, is associated with susceptibility to ulcerative colitis and its progression. Dig Dis Sci. 40:1995;814.
25. Danze P.M., Colombel J.F., Jacquot S., Loste M.N., Heresbach D., Ategbo S., Khamassi S., Perichon B., Semana G., Charron D., Cezard J.P. Association of HLA class II genes with susceptibility to Crohn's disease. Gut. 39:1996;69.
26. Castro R., Yang H., Apple R., Targan S.R., Erlich H.H., Rotter J.I. Inflammatory bowel disease associations with HLA-class II genes. Am J Hum Genet. 55:1994;A148.
27. Reinshagen M., Loeliger C., Kuehnl P., Weiss U., Manfras B.G.A., Boehm B. HLA class II gene frequencies in Crohn's disease a population based analysis in Germany . Gut. 38:1996;583.
28. Forcione D.G., Sands B., Isselbacher K.J., Rustigi A., Podolsky D.K., Pillai S. An increased risk of Crohn's disease in individuals who inherit the class II DRB3*0301 allele. Proc Natl Acad Sci USA. 93:1996;5094.
29. Castro R., Yang H., Apple R., Targan S.R., Erlich H.A., Rotter J.I. Inflammatory bowel disease associations with an HLA-class II DPB1 allele. Am J Hum Genet. 57:1995;A161.
30. Shanahan F., Targan S. Inflammatory bowel disease. Kelley W. Textbook of Internal Medicine. 1989;489 Lippincott, Philadelphia.
31. Saiki R., Walsh P.S., Levenson C.H., Erlich H.A. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc Natl Acad Sci USA. 86:1989;6230.
32. Bugawan T.L., Begovich A.B., Erlich H.A. Rapid HLA-DPB typing using enzymatically amplified DNA and nonradioactive sequence specific oligonucleotide probes. Immunogenetics. 32:1990;231.
33. Scharf S.J., Griffith R.L., Erlich H.A. Rapid typing of DNA sequence polymorphism at the HLA-DRB1 locus using the polymerase chain reaction and non-radioactive oligonucleotide probes. Hum Immunol. 30:1991;190.
34. Trachtenberg E.A., Keyeux G., Bernal J., Erlich H.A. HLA class II analysis by PCR/SSOP typing of nine Amerindian tribes and three African American populations from Colombia. Hum Immunol. 37:(Suppl.):1994;24.
35. Moonsamy P.V., Suraj V.C., Bugawan T.L., Saiki R.K., Stoneking M., Roudier J., Magzoub M.M.A., Hill A.V.S., Begovich A.B. Genetic diversity within the HLA class II region ten new DPB1 alleles and their population distribution . Tiss Antigens. 40:1992;153.
36. Moonsamy P.V., Aldrich C., Petersdorf E.W., Hill A.V.S., Begovich A. Seven new DPB1 alleles and their population distribution. Tiss Antigens. 43:1994;249.
37. Begovich A.B., McClure G.R., Suraj V.C., Helmuth R.C., Fildes N., Bugawan T.L., Erlich H.A., Klitz W. Polymorphism, recombination and linkage disequilibrium within the HLA class II region. J Immunol. 148:1992;249.
38. Imanishi T., Akaza T., Kimura A., Tokunaga K., Gojoberi T. Allele and Haplotype Frequencies for HLA and Complement Loci in Various Ethnic Groups. 1992;Oxford University Press, Oxford.
39. Schlesselman J. Case-Control Studies Design, Conduct, Analysis . 1982;Oxford University Press, New York.
40. Erlich H.A., Zeidler A., Chang J., Shaw S., Raffel L.J., Klitz W., Beshkov Y., Costin G., Pressman S., Bugawan T., Rotter J.I. HLA class II alleles and susceptibility and resistance to insulin dependent diabetes mellitus in Mexican-American families. Nat Genet. 3:1993;358.
41. Noble J., Valdes A., Cook M., Klitz W., Thomson G., Erlich H. The role of HLA class II genes in insulin-dependent diabetes mellitus molecular analysis of 180 Caucasian, multiplex families . Am J Hum Genet. 59:1996;1134.
42. Verreck F.A., Termijtelen A., Koning F. HLA-DRbeta chain residue 86 controls DRalpha-beta dimer stability. Eur J Immunol. 23:1993;1346.